NB 1008

Drug Profile

NB 1008

Alternative Names: Fluzone + 60%W805EC; Influenza mucosal vaccine - NanoBio; Intranasal nanoemulsion vaccine for influenza - NanoBio; Intranasal seasonal influenza vaccine - NanoBio; NanoStatmuscosal influenza vaccine; NB-1008; Transmucosal influenza vaccine - NanoBio

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NanoBio Corporation
  • Class Influenza virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 27 Mar 2013 NanoBio Corporation completes a phase I trial in Influenza virus infections (prevention, in volunteers) in USA (NCT01354379)
  • 23 Jan 2012 NanoBio Corporation completes enrolment in its phase I trial for Influenza virus infections (prevention, in volunteers) in USA (NCT01354379)
  • 13 May 2011 Phase-I clinical trials in Influenza virus infections in USA (Intranasal, spray)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top